Novel role of Egr-1 in nicotine-related neointimal formation

Cardiovasc Res. 2010 Nov 1;88(2):296-303. doi: 10.1093/cvr/cvq213. Epub 2010 Jul 8.

Abstract

Aims: The aim of this study was to investigate the mechanisms by which nicotine increases vascular smooth muscle cell (VSMC) proliferation and post-injury neointimal formation.

Methods and results: Vascular injury was inflicted in the right iliac artery of nicotine-treated and control rats. Nicotine increased post-injury VSMC proliferation (Ki67(+) cells) and neointimal formation (neointima/media ratio, 0.42 ± 0.23 vs. 0.14 ± 0.07, P= 0.02). To determine the mechanisms by which nicotine exacerbates VSMC proliferation, cultured cells were exposed to nicotine, and signalling pathways leading to cell proliferation were studied. Nicotine activated extracellular signal-regulated kinase (ERK) 1/2 in a dose- and time-dependent manner. The blockade of this signalling axis abolished nicotine-mediated proliferation. Functional nicotinic acetylcholine receptors and Ca(2+) influx were necessary for ERK1/2 activation and nicotine-induced mitogenesis in VSMCs. Downstream to ERK1/2, nicotine induced the phosphorylation of Ets-like gene 1 in a timely co-ordinated manner with the up-regulation of the atherogenic transcription factor, early growth response 1 (Egr-1). The treatment of balloon-injured arteries with a lentivirus vector carrying a short hairpin RNA against Egr-1 abolished the deleterious effect of nicotine on vascular remodelling.

Conclusion: Nicotine acts through its receptors in VSMC to activate the ERK-Egr-1 signaling cascade that induces cell proliferation and exacerbates post-injury neointimal development.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Administration, Oral
  • Animals
  • Atherosclerosis / chemically induced*
  • Atherosclerosis / metabolism
  • Atherosclerosis / pathology
  • Atherosclerosis / prevention & control
  • Calcium Signaling / drug effects
  • Catheterization / adverse effects
  • Cell Proliferation / drug effects*
  • Cells, Cultured
  • Chelating Agents / pharmacology
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Early Growth Response Protein 1 / genetics
  • Early Growth Response Protein 1 / metabolism*
  • Enzyme Activation
  • Iliac Artery / drug effects
  • Iliac Artery / metabolism
  • Iliac Artery / pathology
  • Ki-67 Antigen / metabolism
  • Mitogen-Activated Protein Kinase 1 / antagonists & inhibitors
  • Mitogen-Activated Protein Kinase 1 / metabolism
  • Mitogen-Activated Protein Kinase 3 / antagonists & inhibitors
  • Mitogen-Activated Protein Kinase 3 / metabolism
  • Muscle, Smooth, Vascular / drug effects*
  • Muscle, Smooth, Vascular / injuries
  • Muscle, Smooth, Vascular / metabolism
  • Muscle, Smooth, Vascular / pathology
  • Myocytes, Smooth Muscle / drug effects*
  • Myocytes, Smooth Muscle / metabolism
  • Myocytes, Smooth Muscle / pathology
  • Nicotine / administration & dosage
  • Nicotine / toxicity*
  • Nicotinic Agonists / administration & dosage
  • Nicotinic Agonists / toxicity*
  • Nicotinic Antagonists / pharmacology
  • Phosphorylation
  • Protein Kinase Inhibitors / pharmacology
  • RNA Interference
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Nicotinic / drug effects
  • Receptors, Nicotinic / metabolism
  • Time Factors
  • Transfection
  • Tunica Intima / drug effects*
  • Tunica Intima / injuries
  • Tunica Intima / metabolism
  • Tunica Intima / pathology
  • ets-Domain Protein Elk-1 / metabolism

Substances

  • Chelating Agents
  • Early Growth Response Protein 1
  • Egr1 protein, rat
  • Elk1 protein, rat
  • Ki-67 Antigen
  • Nicotinic Agonists
  • Nicotinic Antagonists
  • Protein Kinase Inhibitors
  • Receptors, Nicotinic
  • ets-Domain Protein Elk-1
  • Nicotine
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3